Skip to main content

Point-of-care blood device for fast and reliable prediction of drug response in non- small-cell lung carcinoma patients from blood samples

Objective

Chemotherapy is the standard care for the treatment of non-small cell lung carcinoma (NSCLC) patients, however most of non-small cell lung cancer tumours are not sensitive to this treatment. As an alternative to chemoterapy, target therapy with gefitinib (epidermal growth factor receptor-tyrosine kinase inhibitor) has been used in clinical practice in patients with tumours harbouring mutations in EGFR gene, improving their treatment effectiveness. For that reason EGFR mutations analysis should be perform to support the treatment decision for a patient with NSCLC. Despite all the foreseen benefits of EGFR genotyping, the current PCR-based methods used have been shown some associated bottlenecks: i) use of complex samples (tumour biopsy embedded in Formalin Fixed Paraffin, FFPE), ii) require a better understanding from the clinical geneticist to accurately interpret the information provided and to setup the best line of therapy and treatment and iii) the assays are quite expensive and time-consuming. New age diagnostic tools, such as microfluidic platforms and nanodiagnostics are emerging technologies for DNA analysis requiring lower sample volumes and providing comparable sensitivity and specificity at lower costs. Nonetheless, sample preparation and detection of the result of a chemical analysis on-chip are still weak points in many lab-on-a-chip devices. The current proposal, aiming the integration of “all laboratory-based process steps” in one single step, is both challenging and feasible: development of a microfluidic chip that combines blood sample processing (DNA extraction/purification, multiplex amplification) and detection of EGFR mutations in tumour DNA by means of gold and silver-nanoparticles (Ag and Au-nanoprobes). Furthermore a microfluidic chip analyser with an integrated user-friendly software to report genotyping results will be developed.

Field of science

  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds
  • /natural sciences/biological sciences/genetics and heredity/mutation
  • /natural sciences/computer and information sciences/software
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-SME-2012
See other projects for this call

Funding Scheme

BSG-SME - Research for SMEs

Coordinator

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA
Address
Rua Dos Inventores S/n Edificio Madan Parque Salas 2.18 E 2.19
2825 182 Caparica
Portugal
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 301 782
Administrative Contact
Orfeu Flores (Dr.)

Participants (6)

MICROLIQUID SL
Spain
EU contribution
€ 405 355,60
Address
Avenida Uribarri 19-1 Saiolan
20500 Arrasate Mondragon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Borja Barredo (Mr.)
MOLTECH SRL
Italy
EU contribution
€ 339 213,40
Address
Via Roma 72
86074 Filignano Is
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Giovanni Ugo Altieri (Mr.)
FUNDACAO DA FACULDADE DE CIENCIAS E TECNOLOGIA DA UNIVERSIDADE NOVA DE LISBOA.
Portugal
Address
Campus De Caparica, Quinta Da Torre S/n
2829516 Caparica
Activity type
Research Organisations
Administrative Contact
Ana Luísa Baião (Ms.)
UNIVERSITY OF HULL
United Kingdom
Address
Cottingham Road
HU6 7RX Hull
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Steven Haswell (Prof.)
LEIBNIZ-INSTITUT FUER PHOTONISCHE TECHNOLOGIEN E.V.
Germany
Address
Albert Einstein Strasse 9
07745 Jena
Activity type
Research Organisations
Administrative Contact
Gabriele Hamm (Dr.)
HULL AND EAST YORKSHIRE HOSPITALS NATIONAL HEALTH SERVICE TRUST
United Kingdom
EU contribution
€ 9 649
Address
Anlaby Road Hull Royal Infirmary
HU3 2JZ Hull
Activity type
Research Organisations
Administrative Contact
Michael Lind (Prof.)